



NEWS RELEASE

Contacts:

Dr. W. Dorsey Stuart
Chief Executive Officer
Neugenesis Corporation
650-689-2220
dstuart@neugenesis.com

Dr. Jose Ignacio Martinez
Director of Research
Universidad de los Andes
56-2-330253
jimartinez@uandes.cl

For Immediate Release

NEUGENESIS CORPORATION SIGNS R & D MOU WITH UNIVERSIDAD DE LOS ANDES

November 7, 2008
Burlingame, California, USA
Los Condos, Santiago, Chile

Neugenesis Corporation and Universidad de los Andes announced today the signing of a Memorandum of Understanding (MOU) indicating the desire to enter into a joint venture Research and Development (R&D) project.

Neugenesis will provide their proprietary fungal protein expression platforms for rapid, low-cost, high level protein manufacturing to the project. The Universidad de los Andes will provide the expertise of their Research Professors and state of the art infrastructure, to include Graduate Assistances.

Possible R&D projects include the manufacturing of seasonal influenza vaccine utilizing the Neugenesis proprietary production system, a faster and less expensive method to produce vaccines. A success in this area would help to alleviate the present situation of a shortage of available vaccines in the USA and Chile.

Dr. W. Dorsey Stuart, CEO of Neugenesis says “I am excited to be working with the research professors and staff at the Universidad including Dr. Maria Teresa Valenzuela, a well known Latin American expert in vaccines, especially HPV. This new interaction with the Universidad offers great benefits to both organizations”.

Dr. Jose Ignacio Martinez, Director of Research at the Universidad, is also pleased “because the agreement with Neugenesis was necessary for a new stage in our research in biotechnology”.

Randy Havre, a member of the Neugenesis Board of Directors and a Venture Capitalist in Hawaii, signed the MOU for Neugenesis Corporation and Antonio Jose Guzman, Vicerrector, signed for the Universidad de los Andes. Mr. Havre will be working directly with Dr. Martinez to finalize the Joint Venture project.

About the collaboration team:

Neugenes Corporation

Neugenes Corporation (www. Neugenes.com) has proprietary fungal protein expression platforms for rapid, low-cost, high-level protein manufacturing. The NeuBIOS™ and the NeuKARYON™ platforms allow for rapid generation of production strains expressing a wide range of therapeutic proteins. These platforms are readily scalable and manufacturing requires significantly less infrastructure than traditional methods. In addition to its proprietary position in therapeutics production, Neugenes has proprietary technologies in the area of cell based gene directed evolution and cell based combinatorial biology (CombiKaryon technology).

Universidad de los Andes

Mission

The Universidad de los Andes looks to spread in society a way of life coherent with the Christian truth, that harmonizes faith and reason; To generate and spread new information in all areas of knowledge; To foment attitudes of open and respectful dialogue with the people; To promote the integral development of students, with a personal dedication to each; To spread the love of the good work made and the eagerness on watch, being inspired by the spirit of the Opus Dei that is, in addition, guarantor of the Christian formation that in her is distributed.

Vision

The Universidad de los Andes aspires to become a center of excellence and of source of intellectual habits and morals. The Universidad supports professionals trained in their classrooms in distinguishing themselves by their professional competition, their sense of solidarity, their capacity to responsibly serve society and their ethical action in work. The Universidad supports the spread in society of the divine value of human life, of the good work done and of the truth that frees mankind. The Universidad also supports collaborating with other national and foreign institutions.

#####